Jade Biosciences, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Jade Biosciences, Inc. (JBIO) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $242.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-10
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $242.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $252.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $265.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $305.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $242.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $252.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $265.00K 10-K · filed 2026-03-06 |
| 2025-09-30 | $305.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $361.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $7.00K 10-Q · filed 2025-04-25 |
| 2025-03-01 | $400.00K 10-Q · filed 2026-08-10 |
| 2024-12-31 | $12.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $18.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $29.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $39.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $33.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $43.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $57.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $70.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $86.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $118.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $43.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $51.00K 10-K · filed 2022-03-30 |
| 2021-09-30 | $62.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |